2026-07-21 FDA Warning Letter: Koven Technologies, Inc. Cited for CGMP/QSR/Medical Devices/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/QSR/Medical Devices/Adulterated
TL;DR
In short: # FDA Warning Letter Summary **FDA, Center for Devices and Radiological Health** issued a warning letter (CMS #734643, dated July 21, 2026) to **Koven Technologies, Inc.** (Saint Louis, MO) regarding the **Bidop 3 Doppler** medical device, following an inspection conducted February 2–6, 2026. The FDA determined the device is adulterated under 21 U.S.C. § 351(h) due to non-conformity with Current Good Manufacturing Practice (21 CFR Part 820), specifically: (1) failure to document and approve design changes expanding indications to include fetal applications without demonstrating validation data or determining 510(k) submission necessity; and (2) inadequate risk management analysis failing to evaluate fetal-specific hazards (thermal effects, acoustic exposure, diagnostic accuracy) despite fetal populations being the primary users of the Bidop 3 and Bidop 7 devices. The company initiated a recall via certified mail and submitted a Medical Device Report (RES ID 98556) on March 6, 2026, with corrective actions ongoing as of the letter date.
Argus analysis
# FDA Warning Letter Analysis: Koven Technologies, Inc.
**Company and Findings**
Koven Technologies, Inc., a Saint Louis–based medical device manufacturer, received a warning letter from the FDA's Center for Devices and Radiological Health on July 21, 2026, following an inspection conducted February 2–6, 2026. The inspection focused on the Bidop 3 Doppler (510(k) K954397) and Bidop 7 (510(k) K201114), ultrasound devices marketed for fetal heart rate detection. FDA investigators determined that these devices were adulterated because manufacturing methods, facilities, and controls failed to comply with current good manufacturing practice requirements under the Quality Management System Regulation.
**Regulatory Citations and Violations**
The warning letter cites four primary violations of 21 CFR Part 820 and ISO 13485:2016 standards. First, the company failed to document design control procedures for expanding indications for use to fetal applications without adequate regulatory review or 510(k) resubmission. Second, risk management analyses lacked evaluation of fetal-specific hazards, including thermal effects, acoustic exposure, and risks of cardiac signal misinterpretation that could result in missed fetal distress or unnecessary clinical intervention. Third, supplier evaluation criteria were inadequate; a contract manufacturer implemented undocumented design changes without site assessment or proper quality agreements. Fourth, the company failed to evaluate approximately 13 returned devices reporting failures as formal complaints under 21 CFR 820.35(a), instead categorizing them as routine returns.
**Response Timeline and Industry Observations**
Koven submitted responses on February 27, April 17, and May 28, 2026. FDA noted that corrective actions remain in progress and could not yet determine adequacy. A medical device recall was initiated following a March 6, 2026, adverse event report (RES ID: 98556). Compliance officers in ultrasound and diagnostic device manufacturing should monitor whether Koven submits supplemental 510(k)s, completes CAPA effectiveness documentation, and receives follow-up inspection findings.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Koven Technologies, Inc. MARCS-CMS 734643 — July 21, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Product: Medical Devices Recipient: Recipient Name Heather S. Bell Recipient Title President Koven Technologies, Inc. 477 N. Lindbergh Blvd. Ste. 220 Saint Louis , MO 63141 United States (b)(6), (b)(7)(C) Issuing Office: Center for Devices and Radiological Health United States WARNING LETTER CMS # 734643 July 21, 2026 Dear Ms. Bell: During an inspection of your firm located in Saint Louis, MO, conducted from February 2, 2026, through February 6, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures and/or markets the Bidop 3 Doppler. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. Quality Management System Regulation Violation(s) This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality Management System Regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from Heather Bell, President, on February 27, 2026; April 17, 2026; and May 28, 2026, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include but are not limited to the following: 1. Failure to document procedures to control design and development changes, and determine the significance of these changes to function, performance, usability, safety and regulatory requirements for the medical device and its intended use, as required by ISO 13485:2016 Clause 7.3.9. Specifically, your firm failed to follow procedure 1-SOP-014, Design Control, which states, “All design changes must be identified, documented, where appropriate validated, reviewed and approved before the changes may be implemented.” Additionally, your firm failed to follow procedure 2-SOP-010, Device Registration, Submission and Notification, which requires that once a device or process is changed, (b)(4) . Your firm did not document design and development changes related to expanding the indications for use of the Bidop 3 (K954397) to include a fetal application which was not cleared as an intended use. During the inspection, the Bidop 3 operations manual noted the indications for use include detection of fe…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Koven Technologies, Inc. had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Koven Technologies, Inc. as of 2026-08-04. Argus ingests new FDA enforcement records daily.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). 2026-07-21 FDA Warning Letter: Koven Technologies, Inc. Cited for CGMP/QSR/Medical Devices/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-koven-technologies-inc-2026-07-21-cgmp
"2026-07-21 FDA Warning Letter: Koven Technologies, Inc. Cited for CGMP/QSR/Medical Devices/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-koven-technologies-inc-2026-07-21-cgmp.
Argus HQ Research. "2026-07-21 FDA Warning Letter: Koven Technologies, Inc. Cited for CGMP/QSR/Medical Devices/Adulterated." Digital Empire Holdings LLC. Accessed August 5, 2026. https://argushq.ai/fda/warning-letter/fda-wl-koven-technologies-inc-2026-07-21-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_koven_technologies_inc_2026_07_21_cgmp_2026,
title = {2026-07-21 FDA Warning Letter: Koven Technologies, Inc. Cited for CGMP/QSR/Medical Devices/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-koven-technologies-inc-2026-07-21-cgmp},
note = {Accessed: August 5, 2026}
}